Loading
People with Barrett's oesophagus without dysplasia have endoscopies every few years, but the BOSS trial found no survival benefit. Redirecting effort to those with dysplasia would save harm and cost.
BOSS (UK) randomised surveillance versus at-need endoscopy and found no mortality benefit. Propose guideline change to stop routine surveillance for non-dysplastic short-segment Barrett's, replacing it with capsule sponge or biomarker (p53, TFF3) risk stratification to select the minority for surveillance.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.